GSK gets CHMP backing for Nucala in COPD and depemokimab in asthma, setting up possible Europe approvals in 2026 for IL-5 therapies.

As long as you can work with it, and it’s not affecting your life that much, you don’t consider yourself disabled.” ...

The best thing since sliced bread. That's how patient and former volunteer Lori Gasca describes Tri City Health Partnership, ...

A Massachusetts man in his 40s has been diagnosed with silicosis, an incurable lung disease linked to popular kitchen ...

The UCR accepts referrals from GPs, Hampshire hospitals, ambulance services, families, and patients themselves. It helps ...

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...

GSK secures FDA approval for its oral gonorrhoea drug as EMA backs expanded RSV vaccine and additional respiratory treatments ...

An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

GSK PLC on Friday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the approval of depemokimab in two indications. The London-based pharmaceutical ...

Priority Health, a nationally recognized nonprofit health plan serving more than 1.3 million members, has partnered with Kivo Health, a leading provider of AI-powered virtual pulmonary rehabilitation ...

Background The sit-to-stand (STS) test can assess physical function in people with chronic obstructive pulmonary disease (COPD); however, there are multiple versions. No study has used current ...

Major advancements in pulmonary fibrosis treatment and critical warnings regarding both indoor air quality and scientific ...